Faisal Zain is a distinguished expert in the healthcare technology sector, bringing years of practical experience in the design and manufacturing of advanced medical devices for diagnostics and treatment. His work has consistently focused on the integration of innovative technology into clinical workflows, making him a pivotal figure in the current shift toward precision medicine for large-scale populations. In this discussion, we explore the strategic evolution of “molecular information” companies that bridge the gap between simple diagnostics and long-term drug development. We examine how the declining cost of genomic sequencing, the rise of artificial intelligence, and new risk-sharing business models are enabling a more aggressive approach to treating common chronic illnesses like heart disease. The conversation highlights the move toward longitudinal registries and the ambitious goal of scaling these technologies to reach half a million patients within the next few years.
Many precision medicine models succeeded in oncology by targeting single mutations, but common conditions like heart disease involve a far more complex genetic landscape. How does your approach move beyond the “one mutation, one drug” framework to address these widespread chronic illnesses?
In oncology, the path is often straightforward because we can isolate a specific driver mutation in a tumor and match it to a targeted therapy, but chronic conditions like cardiovascular disease require a much more sophisticated lens. Instead of looking for a single genetic “smoking gun,” we utilize whole genome sequencing to generate comprehensive risk scores that reflect a patient’s overall genetic predisposition to a disease. This approach allows us to define patient populations based on a constellation of many different genetic variants rather than just one. By aggregating this data, we can identify specific therapeutic targets that remain hidden when using traditional diagnostic methods. It is about moving from a binary search for a single mutation to a holistic analysis of the genome to find the most effective intervention points for complex diseases.
The distinction between a “molecular diagnostics company” and a “molecular information company” seems to be the foundation of your business model. Could you explain how generating data serves as a continuous engine for drug development rather than just providing a one-time test result for a patient?
A traditional diagnostics firm typically views the test result as the final product delivered to a clinician, but in our model, that data is actually the beginning of a much larger therapeutic journey. As a molecular information company, we use the genomic data generated from every test to guide the discovery and development of new medicines for common diseases. We are essentially building longitudinal molecular registries that track patient health over a long period, providing a rich, searchable database for identifying novel drug targets. This dual-purpose strategy allows us to support health systems with immediate clinical insights while simultaneously feeding a pipeline of drug development. Every cheek swab we process contributes to a broader ecosystem of knowledge that helps us understand disease progression in a way that isolated diagnostics never could.
We have seen genomic sequencing costs drop significantly and artificial intelligence capabilities skyrocket recently. How have these two factors combined to make the “molecular information” model viable and scalable in the current market?
The economic shift in biotechnology has been dramatic, as the cost of whole genome sequencing has finally fallen to a level where it can be applied to massive patient populations rather than just a select few. This affordability, combined with the fact that many genetic tests are now clinically indicated and reimbursed by payers, has removed the primary financial barriers to entry. Artificial intelligence serves as the essential secondary engine, allowing us to parse through the resulting mountains of genomic data to find patterns and risk scores with incredible speed. Without these automated analytical tools, it would be impossible to manage the data from hundreds of thousands of patients or to accurately match them to specific clinical trials. We are currently leveraging these tailwinds to deploy $30 million in new funding, ensuring we can build a platform that would have been cost-prohibitive just a short time ago.
Your strategy involves a unique “risk-sharing” structure with pharmaceutical companies and the potential to in-license early-stage assets. Why is this more effective than acting as a traditional technology vendor to big pharma?
We chose to move away from the traditional vendor model because we believe that having “skin in the game” leads to more successful drug development outcomes. In our risk-sharing deals, we approach pharmaceutical companies not just with a service, but with a differentiated insight on how to run a smarter, more efficient clinical trial based on our genomic analyses. If our insights lead to a successful drug, we share in the financial upside, which aligns our goals perfectly with the success of the therapy. Additionally, we are constantly scanning the global landscape for early-stage molecules that may have been overlooked or under-developed. When our data reveals a specific patient population that would benefit from one of these molecules, we in-license the asset and incubate a new startup around it right here in our own facility.
From the patient’s perspective, the process of genetic testing can sometimes feel invasive or complicated. How have you streamlined the patient experience, and what are the specific incentives for them to consent to participate in a research biobank?
We have prioritized a frictionless experience by offering simple cheek swabs that can be performed during a routine visit to a cardiologist or primary care physician, or even sent directly to a patient’s home. Once the test is complete, patients have the option to consent to their data being used in a research biobank, which opens up a variety of long-term benefits for them. Not only can they receive additional, updated results as our research evolves, but they also gain the opportunity to be matched with cutting-edge clinical trials tailored specifically to their genetic profile. This turns a one-time diagnostic event into a lifelong partnership in their own health management. By participating, they are no longer just passive recipients of care but are at the forefront of the next generation of precision medicine.
You have already secured partnerships with major health systems like Geisinger and Advocate Health. What are your specific operational goals for the next three years, particularly regarding your international growth and the number of people you aim to sequence?
Our roadmap for the next three years is focused on aggressive scaling, with a target of reaching half a million people sequenced through our various healthcare partnerships. We have already expanded our reach into the United Kingdom to begin international sequencing, and we are looking to grow that footprint into other global markets. With the $30 million in Series A financing we recently secured, we have the capital necessary to sustain this growth and spin out several new biotech companies based on the assets we are currently incubating. By next year, we expect to announce even more partnerships and shared insights from our active discussions with pharmaceutical leaders. Our goal is to transform from a startup into a global infrastructure that supports the development of precision therapies for the world’s most common killers.
What is your forecast for the integration of genomic data into routine primary care over the next five years?
I forecast that by the end of this decade, genomic risk profiling will be as standard and expected as a cholesterol test or a blood pressure reading in every primary care office. We are moving toward a future where every patient’s longitudinal molecular record will follow them through the healthcare system, allowing doctors to predict and prevent chronic diseases years before the first symptoms appear. As we continue to build our registries with partners like Providence Healthcare and Cardiovascular Associates of America, we will see a massive shift from reactive treatment to proactive, precision-based prevention. The data we are collecting today is laying the foundation for a healthcare system where “common” diseases like heart disease are no longer managed through trial and error, but through precise, data-driven interventions. This integration will effectively bridge the gap between biotech innovation and the everyday clinic, making advanced molecular medicine accessible to everyone.
